Percutaneous coronary inter- vention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658 63. 649. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfrac- tionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45 54. 650. Montalescot G, Gallo R, White HD, et al. Enoxaparin versus unfrac- tionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in per- cutaneous coronary intervention patients, an international randomized evaluation) trial. J Am Coll Cardiol Intv. 2009;2:1083 91. 651. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354: 1464 76. 652. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295: 1519 30. 653. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between pro- cedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:1061 5. 654. McGarry TF Jr, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123:1445 51. 655. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between acti- vated clotting time during angioplasty and abrupt closure. Circulation. 1996;93:667 71. 656. Brener SJ, Moliterno DJ, Lincoff AM, et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110:994 8. 657. Tolleson TR, O Shea JC, Bittl JA, et al. 